- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03383822
Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance (NI EGP highBMI)
December 19, 2017 updated by: University Health Network, Toronto
Egulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance
It is well known that the hormone insulin lowers blood glucose in part by acting directly on the liver and reducing hepatic glucose production.
Animal studies have shown that the hormone insulin can act on the brain to indirectly lower glucose production by the liver.
It has previously been shown that a nasal spray can deliver insulin directly to the brain without affecting circulating insulin concentration in humans.
Intranasal spray of insulin suppressed hepatic glucose production in lean subjects.
It is unknown whether this effects is blunted in subjects with insulin resistance.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Each study participant will be admitted to hospital the evening prior to the study.
Following admission each study participant will be provided with a standardized dinner.
At 7am (t=0) the next day we will begin a primed, constant intravenous infusion d2 glucose (a stable isotope of glucose, the enrichment of which can be measured by gas chromatography mass spectrometry, allowing us to calculate endogenous glucose production rates) and continue this for 8 hours.
At the same time (7am) a pancreatic clamp will be started as described above for 8 hours.
Blood samples will be analysed with a glucometer for instant blood glucose readings At 9 am (+120 minutes) intranasal placebo or insulin will be administered.
The insulin (Humalog Lispro 100 IU/ml, Eli Lily, Canada) and placebo (diluent) will be transferred to a metered nasal device (Pharmasystems, Ontario #063636 802721, Item 10271) immediately prior to use.
This device dispenses 0.1ml (10 IU) per puff.
4 x 0.1 ml puffs/vials (2 per nostril) will be administered at rate of 2 (one in each nostril) every 60 seconds.
Blood will be drawn at t=0, 30, 60, 120 and every 10 minutes thereafter for 6 hours.
In order to match peripheral lispro concentrations between study visits, a small dose of Humalog (lispro) insulin will be administered intravenously at 9am, during the placebo arm of the study.
Based on the pharmacokinetics of Humalog lispro (personal communication from Eli Lilly), we propose to administer 0.005 IU/kg over 30 minutes.
20% dextrose will be administered to maintain euglycemia as necessary.
Insulin, glucagon, and glucose isotopic enrichment will be measured.
The enrichment data and glucose infusion will be used to calculate steady state glucose production.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1L7
- Tornto General Hospital, UHN
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 58 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women, aged 18 to 60 years
- Body mass index >30 kg/m2
- Hemoglobin in the normal range.
- Normal glucose tolerance in response to a 75g, 2-hr oral glucose tolerance test
- Women of reproductive age should be on contraception (oral contraceptive pill or intra-uterine device/coil) for at least 2 months prior to and after the study.
Exclusion Criteria:
- Study participant with a history of hepatitis/hepatic disease that has been active within the previous two years.
- Any current or previous history of biliary disease (including gall stones, biliary atresia and cholecystitis) or pancreatitis.
- Any current or previous history of endocrine disease, dyslipidemia or malignancy
- Any significant active (over the past 12 months) disease of the gastrointestinal, pulmonary, neurological, renal (Cr > 1.5 mg/dL) genitourinary, hematological systems, or has severe uncontrolled treated or untreated hyper/ hypotension (sitting diastolic BP > 100 or systolic > 180 or systolic BP<100) or proliferative retinopathy
- Use of immunosuppressive agents at any time during the study
- Allergy to any study medication
- Pregnancy or breastfeeding
- Heavy smoker
- Prior nasoduodenal tube insertion under fluoroscopic guidance.
- Fasting blood glucose > 6.0 mmol/l or known diabetes.
- Any history of a myocardial infarction or clinically significant, active, cardiovascular history including a history of arrhythmia's or conduction delays on electrocardiogram, unstable angina, or decompensated heart failure.
- Any nasal pathology likely to affect absorption of insulin or insertion of nasoduodenal tube.
- Any laboratory values: aspartate transaminase > 2x upper limit of normal; alanine aminotransferase > 2x upper limit of normal; thyroid-stimulating hormone > 6 micro unit/l
- Current addiction to alcohol or substances of abuse as determined by the investigator.
- Mental incapacity, unwillingness or language barrier precluding adequate understanding or cooperation
- Taking any regular prescription or non-prescription medications at the time of the study. Occasional use of medications such as acetoaminophen or Tylenol 1 or any use of natural health products may be permitted at the discretion of the investigator.
- Will not donate blood three months prior to and three months post study procedures
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intranasal insulin
40 IU of intranasal insulin
|
Humalog lispro 40 IU intranasally
Other Names:
|
Placebo Comparator: Intranasal placebo
Placebo comparator to intranasal insulin
|
Diluent intranasally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endogenous glucose production
Time Frame: 8 hours
|
Effects of intranasal insulin and placebo on endogenous glucose production will be assessed
|
8 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 8, 2015
Primary Completion (Actual)
July 31, 2017
Study Completion (Actual)
December 1, 2017
Study Registration Dates
First Submitted
December 19, 2017
First Submitted That Met QC Criteria
December 19, 2017
First Posted (Actual)
December 26, 2017
Study Record Updates
Last Update Posted (Actual)
December 26, 2017
Last Update Submitted That Met QC Criteria
December 19, 2017
Last Verified
December 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NI EGP highBMI 12-5032A
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Resistance
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedEndoplasmic Reticulum Stress | HIV Related Insulin Resistance | Protease Inhibitor Related Insulin ResistanceUnited States
-
German Diabetes CenterYale UniversityRecruiting
-
Paloma Almeda-ValdésCompleted
-
National Institute of Diabetes and Digestive and...Active, not recruitingSevere Insulin ResistanceUnited States
-
Eunice Kennedy Shriver National Institute of Child...Completed
-
National Taiwan UniversityNational Cheng-Kung University HospitalCompletedExercise, Insulin Resistance, Visceral Adipose TissueTaiwan
-
Assiut UniversityCompleted
-
University Health Network, TorontoCompletedInsulin Resistance Syndrome X | Pancreatic Beta Cell FunctionCanada
-
University of Colorado, DenverRecruitingEndothelial Dysfunction | Vascular Stiffness | Insulin Sensitivity/Resistance | TransgenderismUnited States
-
University of Texas, El PasoCompletedInsulin Sensitivity/ResistanceUnited States
Clinical Trials on Intranasal insulin
-
Michigan State UniversityCompletedExercise | InsulinUnited States
-
Wake Forest University Health SciencesCompleted
-
Texas Tech University Health Sciences CenterCompletedHypogonadotropic HypogonadismUnited States
-
University of BirminghamQueen Elizabeth Hospital NHS Foundation TrustCompleted
-
Johns Hopkins UniversityTerminatedHIV Dementia | HIV-Associated Cognitive Motor ComplexUnited States
-
University Health Network, TorontoCompletedInsulin Resistance, DiabetesCanada
-
Centre for Addiction and Mental HealthRecruitingDepression | Major Depressive DisorderCanada
-
HealthPartners InstituteJuvenile Diabetes Research Foundation; International Diabetes Center at Park...TerminatedType1diabetesUnited States
-
Rutgers, The State University of New JerseyAlzheimer's AssociationRecruitingMetabolic Syndrome | Alzheimer Disease | Mild Cognitive ImpairmentIsrael
-
VA Connecticut Healthcare SystemRecruiting